Efficacy and Safety of Frexalimab In Participants with Relapsing Multiple Sclerosis: 3-Year Results from the Phase 2 Open-Label Extension Posted byRachelle Ramirez June 24, 2026June 24, 2026 Leave a comment on Efficacy and Safety of Frexalimab In Participants with Relapsing Multiple Sclerosis: 3-Year Results from the Phase 2 Open-Label Extension Stephen Krieger, MD
